Repligen Corporation

Repligen Corporation

Biotechnology Research

Waltham, MA 33,015 followers

About us

FRAUD ALERT: Please take note that it has come to our attention that individuals purporting to work for Repligen are reaching out to prospective job applicants using fraudulent email addresses. All legitimate communications from Repligen will be sent from an individual with an email address ending in @repligen.com. If you have any concerns that a communication may be fraudulent and you would like to confirm whether it is, you may email [email protected] and someone will respond. Repligen is a bioprocessing-focused life sciences company bringing over 40 years of expertise and innovation to our customers. We are inspiring advances in bioprocessing through the development and commercialization of high-value products and flexible solutions that address critical steps in the production of biologic drugs, principally monoclonal antibodies. Repligen headquarters is in Waltham, Massachusetts and our manufacturing facilities are located around the world. We market our products globally through a direct commercial organization in the U.S., Europe and Asia, as well as through strategic partners in select markets.

Website
https://www.repligen.com
Industry
Biotechnology Research
Company size
1,001-5,000 employees
Headquarters
Waltham, MA
Type
Public Company
Specialties
life sciences, biologics manufacturing, bioprocess development, chromatography, Protein A, growth factors, pre-packed columns, perfusion, tangential flow filtration, alternating tangential flow filtration, bioprocessing, hollow fibers, flat sheet cassettes, analytics, bioprocess, bioprocessing, gene therapy, tff systems, and flowpaths

Products

Locations

Employees at Repligen Corporation

Updates

Affiliated pages

Similar pages

Browse jobs

Stock

RGEN

NASDAQ

20 minutes delay

$138.61

4.34 (3.232%)

Open
134.27
Low
134.27
High
138.787

Data from Refinitiv

See more info on Bing

Funding

Repligen Corporation 6 total rounds

Last Round

Post IPO debt

US$ 600.0M

See more info on crunchbase